当前位置:首页 - 行情中心 - 山河药辅(300452) - 财务分析 - 利润表

山河药辅

(300452)

  

流通市值:27.53亿  总市值:34.56亿
流通股本:1.87亿   总股本:2.34亿

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入696,502,709.9470,839,549.6247,871,756.3882,573,320.58
  营业收入696,502,709.9470,839,549.6247,871,756.3882,573,320.58
二、营业总成本570,301,274.26380,930,612.37200,329,332.3733,237,567.43
  营业成本474,492,384.08318,666,886.64167,658,629.29608,623,452.47
  税金及附加7,595,970.815,182,848.332,627,748.849,076,050.92
  销售费用21,355,478.1314,235,260.597,331,103.9829,409,731.88
  管理费用26,092,398.1815,750,869.077,498,467.5934,848,568.06
  研发费用31,868,425.5922,051,834.8412,333,757.3340,952,648.76
  财务费用8,896,617.475,042,912.92,879,625.2710,327,115.34
  其中:利息费用9,771,583.056,406,295.583,157,193.9812,732,444.71
  其中:利息收入962,224.76643,256.5356,517.76946,672.16
三、其他经营收益
  加:公允价值变动收益1,236,270.722,367,019.33-526,013.84-3,134,923.69
  加:投资收益11,886,128.196,232,128.162,586,319.419,229,435.52
  资产处置收益-371,211.49-296,889.16-55,806.89109,338.5
  资产减值损失(新)----39,126,854.84
  信用减值损失(新)-9,841.5-12,701.9-12,996.672,695.63
  其他收益11,315,117.297,297,880.443,616,786.9116,851,939.54
四、营业利润150,257,898.85105,496,374.153,150,712.91143,267,383.81
  加:营业外收入301,633.55213,057.8771,830.8951,646.01
  减:营业外支出194,934.4594,613.4914,627.9963,616.56
五、利润总额150,364,597.95105,614,818.4853,207,915.9142,355,413.26
  减:所得税费用17,827,427.5212,380,054.936,549,549.6921,830,459.63
六、净利润132,537,170.4393,234,763.5546,658,366.21120,524,953.63
(一)按经营持续性分类
  持续经营净利润132,537,170.4393,234,763.5546,658,366.21120,524,953.63
(二)按所有权归属分类
  归属于母公司股东的净利润132,563,910.3793,035,152.0447,176,895.69119,424,741.26
  少数股东损益-26,739.94199,611.51-518,529.481,100,212.37
  扣除非经常损益后的净利润119,577,509.5884,754,011.3344,631,590.1101,157,550.11
七、每股收益
  (一)基本每股收益0.570.40.20.51
  (二)稀释每股收益0.550.380.190.51
九、综合收益总额132,537,170.4393,234,763.5546,658,366.21120,524,953.63
  归属于母公司股东的综合收益总额132,563,910.3793,035,152.0447,176,895.69119,424,741.26
  归属于少数股东的综合收益总额-26,739.94199,611.51-518,529.481,100,212.37
公告日期2025-10-212025-08-272025-04-232025-04-23
审计意见(境内)标准无保留意见
TOP↑